Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age
NA
Primary Objective:
To describe the persistence of Hep B antibodies (Ab) at...
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe
PHASE3
Primary objective:
This study aimed to demonstrate the non-inferiority of ...
Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants
PHASE1
This study is the first study of Sanofi's Pentavalent Meningococcal ABCYW v...
Status
Active Not Recruiting
Location
Hospital das Clínicas da Universidade Federal de Minas Gerais- Site Number : 0760001
Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth
PHASE3
The purpose of this study is to describe the immunogenicity and safety of S...